Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have been assigned a consensus rating of "Reduce" from the nine brokerages that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $30.75.
A number of equities analysts recently issued reports on the stock. Barclays reiterated an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. Kepler Capital Markets cut shares of Galapagos from a "hold" rating to a "reduce" rating in a report on Wednesday, November 20th. TD Cowen lowered shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Finally, Royal Bank of Canada dropped their price target on shares of Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a report on Friday, November 1st.
Check Out Our Latest Report on Galapagos
Galapagos Trading Up 1.3 %
Galapagos stock traded up $0.29 during mid-day trading on Friday, hitting $23.07. The company had a trading volume of 150,306 shares, compared to its average volume of 304,613. Galapagos has a 12 month low of $22.36 and a 12 month high of $40.34. The stock's 50 day moving average price is $25.76 and its two-hundred day moving average price is $27.15.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in GLPG. Crossmark Global Holdings Inc. purchased a new position in shares of Galapagos in the third quarter valued at about $1,077,000. Creative Planning bought a new stake in Galapagos during the 2nd quarter valued at approximately $456,000. Millennium Management LLC lifted its holdings in Galapagos by 5.3% in the 2nd quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company's stock worth $8,466,000 after purchasing an additional 17,089 shares in the last quarter. Finepoint Capital LP grew its holdings in Galapagos by 2.8% during the 3rd quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company's stock valued at $16,058,000 after buying an additional 15,000 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in Galapagos during the 3rd quarter valued at approximately $410,000. Institutional investors own 32.46% of the company's stock.
About Galapagos
(
Get Free ReportGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Read More
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
